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Idiosyncratic adverse drug reactions are unpredictable, dose-in-
dependent and potentially life threatening; this makes them
a major factor contributing to the cost and uncertainty of drug
development. Clinical data suggest that many such reactions
involve immune mechanisms, and genetic association studies have
identiﬁed strong linkages between drug hypersensitivity reactions
to several drugs and speciﬁc HLA alleles. One of the strongest such
genetic associations found has been for the antiviral drug
abacavir, which causes severe adverse reactions exclusively in
patients expressing the HLA molecular variant B*57:01. Abacavir
adverse reactions were recently shown to be driven by drug-spe-
ciﬁc activation of cytokine-producing, cytotoxic CD8
+ T cells that
required HLA-B*57:01 molecules for their function; however, the
mechanism by which abacavir induces this pathologic T-cell re-
sponse remains unclear. Here we show that abacavir can bind
within the F pocket of the peptide-binding groove of HLA-
B*57:01, thereby altering its speciﬁcity. This provides an explana-
tion for HLA-linked idiosyncratic adverse drug reactions, namely
that drugs can alter the repertoire of self-peptides presented to T
cells, thus causing the equivalent of an alloreactive T-cell response.
Indeed, we identiﬁed speciﬁc self-peptides that are presented only
in the presence of abacavir and that were recognized by T cells of
hypersensitive patients. The assays that we have established can
be applied to test additional compounds with suspected HLA-
linked hypersensitivities in vitro. Where successful, these assays
could speed up the discovery and mechanistic understanding of
HLA-linked hypersensitivities, and guide the development of safer
drugs.
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bacavir is a nucleoside analog that suppresses HIV repli-
cation. In approximately 8% of recipients, abacavir is as-
sociated with signiﬁcant immune-mediated drug hypersensitivity,
which is strongly associated with the presence of the HLA-
B*57:01 allele (1, 2). Three complementary models for the
mechanism of immune-mediated severe adverse drug reactions
have traditionally been discussed (3, 4). The hapten (or pro-
hapten) model states that drugs and their metabolites are too
small to be immunogenic on their own, but rather act like
haptens and modify certain self-proteins in the host that lead to
immune recognition of the resulting hapten–self-peptide com-
plexes as de novo antigens (5–7). The pharmacologic interaction
with immune receptors (p-i) model states that drugs can induce
the formation of HLA–drug complexes that can activate T-cell
immune responses directly without requiring a speciﬁc peptide
ligand (8). The danger model, which is in principle compatible
with other models, states that danger signals other than the drug
itself (e.g., chemical, physical, or viral stress) are required to
overcome immune tolerance barriers that otherwise suppress
drug hypersensitivity reactions (7).
None of these existing models provides a convincing mecha-
nism explaining how abacavir induces adverse reactions through
the activation of CD8
+ cells in a strictly HLA-B*57:01–re-
stricted manner, as was described in a groundbreaking paper by
the McCluskey group (2). For the hapten hypothesis to apply,
abacavir would need to modify one or more self-ligands that are
presented solely by HLA-B*57:01 (Fig. 1), an unlikely proposi-
tion given that HLA molecules are known to fall in groups of
overlapping binding speciﬁcity and that HLA-B*57:01 has
a similar binding motif to the abacavir-insensitive HLA-B*58:01
(9). In addition, no natural HLA-speciﬁc drug haptenated pep-
tide has been identiﬁed to date, although this has been
attempted, at least for carbamazepine (10, 11). For the p-i model
to apply, abacavir would need to bind to a unique surface patch
of HLA-B*57:01 that is capable of inducing TCR recognition.
However, the two residues that distinguish abacavir-sensitive
HLA-B*57:01 from abacavir-insensitive HLA-B*57:03 are lo-
cated at the bottom of the HLA-binding groove and are unlikely
to contact the T-cell receptor. Finally, the danger model might
well be relevant for adverse reactions to abacavir, but does not
explain its HLA restriction. We ﬁnd an alternative hypothesis
more attractive, namely that the binding groove of HLA-
B*57:01 can accommodate abacavir (12), thereby altering the
repertoire of self-peptide ligands that are bound and presented
(2, 10). This could lead to a primary and polyclonal immune
response, which is in line with observations that abacavir can
induce a relatively diverse response in T cells from abacavir-
naïve individuals after in vitro stimulation for 11 d (2), with
broad use of V beta receptors by the responding T cells (2).
However, to date there has been no experimental evidence
supporting this “altered self-repertoire” hypothesis as a mecha-
nism for drug hypersensitivity.
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To determine whether abacavir can impact the peptide-binding
speciﬁcity of HLA-B*57:01, we tested its binding afﬁnity using
positional scanning combinatorial peptide libraries (13) in the
presence and absence of the drug. Each library consisted of 9-
mer peptides that share the same residue at one position but
were otherwise random in sequence. In the absence of abacavir,
our binding measurements reproduced the known motif of
HLA-B*57:01 for C-terminal peptide residues, namely a pref-
erence for large hydrophobic residues such as tryptophan and
phenylalanine and a disfavoring of small hydrophobic residues
like alanine and valine (Fig. 2A). We were speciﬁcally in-
terested in residues showing an increased afﬁnity in the pres-
ence of abacavir, which could potentially lead to presentation of
de novo peptides. The most dramatic gains were seen for
peptides with C-terminal valine (8.8-fold increase), alanine
(6.7-fold increase), and isoleucine (5.5-fold increase). The only
other residue with a ﬁvefold or greater increase was leucine at
position 7 (SI Appendix,T a b l eS 1 ). In contrast, the control
MHC molecule HLA-B*58:01 showed no increases in afﬁnity
exceeding threefold for any residue at any position (Fig. 2B and
SI Appendix,T a b l eS 2 ).
Based on these results, we synthesized individual peptides with
the sequence HSITYLLPV (pep-V) and HSITYLLPW (pep-W).
Residues 1–8 of these peptides were chosen based on their high
afﬁnity in combinatorial library scans in the presence of abacavir.
The C terminus was chosen so that pep-V was expected to be
unable to bind efﬁciently in the absence of abacavir, but would
do so in its presence. As a control, pep-W with a C-terminal
tryptophan was expected to be able to bind HLA-B*57:01 readily
in the presence or absence of abacavir. The peptides were
radiolabeled and tested for binding in increasing concentrations
of abacavir. Peptide binding assays demonstrated that pep-V
requires abacavir in a dose-dependent manner to bind a detect-
able amount of peptide (Fig. 2C), whereas pep-W bound well
regardless of the presence or absence of abacavir (Fig. 2D).
Similar results were obtained using two independent peptide–
HLA-B*57:01 interaction assays measuring either binding (14)
or stability (15) (SI Appendix, Fig. S1) and an additional control
allele, HLA-B*57:03 (SI Appendix, Table S3). In summary, we
found that speciﬁc peptides such as pep-V have a signiﬁcantly
increased afﬁnity for HLA-B*57:01 in the presence of abacavir,
that this effect is abolished when the C-terminal P9 residue is
switched to a tryptophan (pep-W), and that this effect is not
observed for control HLA alleles.
Structural analysis was used to further dissect the mechanism
by which abacavir may facilitate the binding of pep-V to HLA-
B*57:01. Computational solvent mapping (16), molecular dock-
ing (17), and molecular dynamics simulations (18) of 30 ns in
length identiﬁed a potential binding site for abacavir localized to
the F pocket in the vicinity of residue Ser-116, which has been
shown to be required for abacavir T-cell recognition (2) (SI
Appendix, Fig. S2). In contrast, a similar protocol did not identify
stable complexes of MHC, abacavir, and peptide with either pep-
W or abacavir-insensitive HLA-B*57:03.
To directly test our hypothesis that abacavir binds within the
antigen-binding cleft, we solved the X-ray crystal structure of
HLA-B*57:01 bound to pep-V in the presence of abacavir. We
believe that choosing pep-V instead of a ligand with a large side
chain at the C terminus, such as those used in previous crystal
structures (2), was crucial to obtaining crystals that could resolve
the location of abacavir. The structure was reﬁned to an R value
of 18% and an Rfree value of 22% using X-ray diffraction data to
2.0 Å (PDB ID: 3UPR); details are provided in Materials and
Methods, and complete reﬁnement statistics are presented in SI
Appendix, Table S4. Abacavir is bound to a largely hydrophobic
pocket in the antigen-binding cleft forming van der Waals con-
tacts with both HLA-B*57:01 (Tyr9, Tyr-74, Ile-95, Val97, Tyr99,
Tyr123, Ile-124, and Trp147) and pep-V (Ile3, Leu7, and Val9)
(Fig. 3A and SI Appendix, Fig. S3).
To determine whether the conformation of pep-V is altered by
abacavir binding compared with conventionally presented pep-
tides, we compared our structure with four published structures
of peptides bound to HLA-B molecules. The main chain con-
formation of pep-V is similar to that of other peptides bound to
HLA-B (Fig. 3D). The amino and carboxy termini of pep-V and
the other HLA-B–bound peptides shown in Fig. 3D are buried in
the A and F pockets, respectively, forming conventional contacts
with highly conserved residues. The central portion of the pep-V
main chain is within the range of variability demonstrated by
other peptide–HLA-B complexes. The pep-V main chain does
not protrude in a central bulge as does the longer 11-mer peptide
bound to HLA-B*35:01. These data suggest that pep-V in the
presence of abacavir is bound in a regular antigen conformation,
allowing for conventional recognition by TCRs rather than the
need for hapten or superantigen recognition modes (19, 20).
Only two residues, Asp114 and Ser116, distinguish HLA-
B*57:01 from the abacavir-insensitive allele HLA-B*57:03.
Abacavir interacts directly with these residues (Fig. 3 C and E).
The Oδ1 atom of Asp114 is within H bonding distance of the
main purine group N2 and N3 atoms of abacavir. The hydroxyl
group of Ser116 forms an H bond with the 2-amino group on the
purine ring of abacavir. The exchange of Ser116 to Tyr116 seen
in HLA-B*57:03 is expected to disrupt these interactions. In-
deed, it was shown that this single residue exchange is sufﬁcient
to abrogate abacavir-associated recognition by CD8
+ T cells (2).
The HLA-B*58:01 allelic variant is also very similar to HLA-
B*57:01. These molecules have identical amino acids at positions
114 and 116 but different amino acids at ﬁve other positions.
These include Val97, part of the hydrophobic pocket in HLA-
Fig. 1. Schematic presentation of HLA antigen presentation and HLA-linked
mechanisms of adverse reactions. (Upper) T-cell receptors monitor the uni-
verse of antigens to which an individual is exposed by surveying the ligands
presented on an antigen-presenting cell membrane in the context of HLA
molecules. The HLA ligands are typically peptides loaded onto the HLA
molecule inside the antigen-presenting cells and subsequently exposed on
the surface. Different allelic variants of HLA molecules have different
binding speciﬁcities, resulting in a speciﬁcp r o ﬁle of presented ligands. In
the example shown, peptide A, but not peptide B, can bind to the HLA
molecule. Self-peptides presented to T cells in this manner do not trigger an
immune response, because T cells that are self-reactive are negatively se-
lected during thymic development. However, when T cells encounter an
unknown ligand (eg, a virus-derived peptide), an immune response is trig-
gered. (Lower) There are three scenarios for HLA-dependent drug-induced
modiﬁcations that affect the TCR interface: (1) A ligand that is uniquely
presented by the HLA allele is modiﬁed by the drug; (2) the HLA molecule
itself is modiﬁed in a region exposed to the TCR; and (3) the binding spec-
iﬁcity of the HLA molecule is altered by the presence of the drug, resulting in
presentation of novel ligands such as peptide B.
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Appendix, Fig. S3), which is replaced with a charged Arg97 in
HLA-B*58:01, abrogating these interactions. In addition, the
structure reveals that the side chain of Val9 of pep-V is within
van der Waals contact distance of the cyclopropyl moiety of
abacavir. Finally, the contact made between the Leu7 residue of
the peptide and abacavir explains why the MHC binding assays
showed that this residue had the highest increase in afﬁnity in the
presence of abacavir apart from C-terminal residues. In sum-
mary, our ﬁndings give a structural explanation for why distinct
repertoires of peptides with short hydrophobic P9 side chains are
bound by HLA-B*57:01 in the presence of abacavir, whereas
other HLA alleles are unaffected.
To explore the biological relevance of these ﬁndings, we de-
termined whether live cells treated with abacavir present a dif-
ferent set of self-peptides on HLA-B*57:01 molecules compared
with untreated cells. Our binding assays predicted that HLA-
B*57:01 in the presence of abacavir would favor presentation of
peptides with a small C-terminal residue, such as valine and
isoleucine, rather than the tryptophan and phenylanine normally
preferred by HLA-B*57:01 molecules. To answer this question,
we eluted peptides from an HLA-B*57:01 single allele-trans-
fected 721.221 cell line (21) treated with and without abacavir.
Eluted peptides were analyzed by nanoﬂow-HPLC coupled to an
orbitrap mass spectrometer equipped with front-end electron
transfer dissociation (22, 23). We identiﬁed 539 and 682 peptide
sequences from the drug-treated and untreated samples, re-
spectively, 287 of which were found in both samples (SI
Appendix, Table S5). No peptides with valine at the C terminus
were identiﬁed in untreated cells, but 15 peptides with valine at
the C terminus were identiﬁed in the presence of abacavir. Three
of these peptides were present at levels (>100 copies/cell) that
place them among the top 5% of all peptides in the drug-treated
sample. Table 1 compares the frequency of C-terminal residues
in peptides identiﬁed uniquely in either the abacavir-treated or
untreated samples. In the presence of abacavir, there was sig-
niﬁcant enrichment not only for peptides with valine at the C
terminus, but also for isoleucine. In contrast, there were signif-
icantly fewer peptides with tryptophan and phenylalanine at the
C terminus. The results for these residues match exactly the
predictions made by the binding assays. In contrast to valine, no
peptides with C-terminal alanine were discovered in the pres-
ence of abacavir, even though both showed a similar increase in
afﬁnity. However, the absence of peptides with an alanine at the
C terminus can be explained by the antigen processing machin-
ery, including proteasomal cleavage and TAP transport, which
restricts the peptide repertoire available for binding to MHC and
disfavors peptides with C-terminal alanine (24, 25). In summary,
we ﬁnd that the self-peptide repertoire presented by HLA-
B*57:01–positive cells in the presence of abacavir is signiﬁcantly
altered in a manner consistent with results obtained from the
molecular MHC binding assays.
Finally, we set out to determine whether we could detect T
cells in hypersensitive patients who recognize HLA-B*57:01–
restricted peptides that are presented only in the presence of
abacavir. Of note, we did not expect to see high-frequency T-cell
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Fig. 2. The presence of abacavir alters the binding speciﬁcity of HLA-B*57:01. (A and B) Combinatorial peptide libraries were tested for binding to HLA-
B*57:01 (A) and HLA-B*58:01 (B) in competitive binding assays as described previously (13, 39). Results for libraries with different C-terminal residues are
shown for those residues with afﬁnities of 5,000 nM or better, a minimal threshold for binding. Error bars indicate 95% conﬁdence intervals for the mean,
and residues marked with an asterisk had signiﬁcantly different IC50 values in the presence vs. absence of abacavir (P < 0.001, two-tailed Student t test
comparing log IC50 values). The most pronounced afﬁnity increases for HLA-B*57:01 in the presence of 1 mg/mL of abacavir were found for peptides with
a valine at the C terminus, which increased by more than eightfold, followed by alanine and isoleucine, which increased by ﬁvefold. In contrast, the maximum
afﬁnity increase for any peptide library binding to HLA-B*58:01 was less than threefold. (C and D) Individual peptides HSITYLLPV (pep-V) and HSITYLLPW
(pep-W) were radiolabeled and tested for binding to HLA-B*57:01 and B*58:01 in increasing doses of abacavir. After washing, no pep-V binding to HLA-
B*57:01 was detectable in the absence of abacavir, but strong binding was detected in the presence of abacavir. No signiﬁcant effect of abacavir was ob-
served for pep-W binding to HLA-B*57:01.
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ligand mechanism suggests that the response is directed against
a very large number of different peptides. We screened peripheral
blood mononuclear cells (PBMCs) from ﬁve HLA-B*57:01–
positive donors with a clinical history of abacavir hypersensitivity
for recognition of peptides with valine at the C terminus that
were identiﬁed after elution from abacavir-treated HLA-B*57:01
cells. The PBMCs were incubated for 15 min with a high con-
centration of 10 μg/mL of endogenous peptides in the pre-
sence of 100 μg/mL of abacavir, followed by washing to optimize
loading of HLA-B*57:01 with the speciﬁc exogenously added
peptide(s), reduce the abacavir entering cells, and enable pre-
sentation of other endogenous ligands. After a ﬁrst round of
screening four pools of three or four peptides in ELISPOT
assays using PBMCs from two donors with sufﬁcient samples
available, the peptides from the pool with the highest response
(pool 1) were tested individually. Peptide VTTDIQVKV showed
the greatest response in this screen (SI Appendix,F i g .S 4 ).
Subsequently, we tested the four pools and the individual pep-
tide VTTDIQVKV in the remaining three donors. A signiﬁ-
cantly greater response was detected when cells were pulsed
w i t hp e p t i d eV T T D I Q V K Va n da b a c a v i rc o m p a r e dw i t ht h e
response against cells pulsed with either abacavir alone or
peptide alone (Fig. 4). These data demonstrate that memory
T-cell responses in abacavir-hypersensitive donors are directed
against a self-peptide that requires abacavir to efﬁciently
bind HLA-B*57:01.
Discussion
Our ﬁndings provide a mechanistic explanation for abacavir-in-
duced adverse drug reactions. We found that abacavir can bind
inside the peptide-binding groove of HLA-B*57:01, thereby
enabling the presentation of peptide ligands that normally can-
not bind in substantial amounts. Because T cells are generally
tolerant only to MHC-restricted peptide ligands presented dur-
ing T-cell development in the thymus (26), presentation of an
altered repertoire of class I MHC binding peptides will be per-
ceived as being foreign and trigger CD8
+ T-cell responses. These
responses have been shown to be a hallmark of patients with
abacavir hypersensitivity (2). Although abacavir is metabolized
inside cells (27, 28), our ﬁnding that HLA-B*57:01 is affected by
the abacavir parent drug suggests that the parent drug itself is
present during peptide loading in the endoplasmic reticulum
Fig. 3. Crystal structure of the abacavir–peptide–MHC complex solved to
a resolution limit of 2.0 Å reveals intermolecular contacts within the anti-
gen-binding cleft. (A) Cartoon diagram of HLA-B*57:01 in gray. The peptide
HSITYLLPV is shown in cyan carbons. Abacavir is shown as spheres, orange
for carbon, blue for nitrogen and red for oxygen. (B) Chemical structure of
abacavir, with the cyclopropyl moiety shown in green, the purine core in
blue, and the hydroxymethyl cyclopentene moiety in red. (C) Abacavir
forms H bond interactions (black dashes) with both the peptide and HLA-
B*57:01. The residues that distinguish the abacavir-sensitive allele HLA-
B*57:01 from abacavir-insensitive HLA-B*57:03 are shown in magenta for
carbon, blue for nitrogen, and red for oxygen. (D) Abacavir binding in the F
pocket does not alter the peptide conformation compared with other
peptide/HLA-B complexes. A cartoon representation of peptide in the
crystal structure complexed to abacavir and HLA-B*57:01 is shown in cyan
(HSITYLLPV; PDB ID: 3UPR). A 9-mer self peptide (LSSPVTKSF) complexed to
HLA-B*57:01 (PDB ID: 2RFX (2) is shown in red, the 8-mer peptide epitope
HIV1 Nef 75–82 (VPLRPMTY) bound to HLA-B*35:01 (PDB ID: 1A1N) (40) is
shown in pink, a 9-mer EBV peptide (FLRGRAYGL) complexed to HLA-B8
(PDB ID: 1MI5) (41) is shown in green, and the 11-mer EBV peptide
HPVGEADYFEY complexed to HLA-B*35:01 (PDB ID: 3MV9) (42) is shown in
yellow. The molecular surface of HLA-B*57:01 from 3UPR is shown in gray.
The F pocket residues (9) are colored green, and the A pocket is yellow. (E)
Experimental electron density corresponding to abacavir in an Fo-Fc dif-
ference map contoured at 3.5σ (red mesh) after molecular replacement.
Gray mesh depicts the ﬁnal 2Fo-Fc electron density map of abacavir in the
antigen-binding cleft of HLA-B*57:01 (contour level, 1.5σ). H bond inter-
actions between abacavir and HLA-B*57:01 are shown as yellow dashed
lines. The residues that distinguish the abacavir-sensitive allele HLA-B*57:01
from abacavir-insensitive HLA-B*57:03 are shown in magenta for carbon,
blue for nitrogen, and red for oxygen.
Table 1. Distribution of C-terminal residues in peptides
uniquely presented by abacavir treated and untreated cells
C-terminal residue
Abacavir
P value* Untreated Treated
W 218 ↓ 95 2E-05
F8 9 ↓ 31 1E-03
Y 42 33 0.38
L 25 25 0.10
I1 4 ↑ 45 1E-09
M 6 7 0.39
V0 ↑15 5E-07
*Two-tailed Fisher exact test. All C-terminal residues for which two or more
peptides were identiﬁed are listed.
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Fig. 4. T cells from hypersensitive donors respond to speciﬁc self-peptides in
an abacavir- dependent fashion. PBMCs from ﬁve HLA-B*57:01-positive
donors with a clinical history of abacavir hypersensitivity were pulsed for
15 min with peptide antigens in the presence or absence of abacavir or with
abacavir alone, washed, and then tested by an IFN-γ ELISpot assay (Materials
and Methods). The ﬁgure shows the calculated mean (± SEM) IFN-γ spots per
million input PBMCs. Statistically signiﬁcant responses compared with the
response induced by the abacavir pulse alone were obtained for peptide
pool 1 and the individual peptide VTTDIQVKV (paired two-tailed Student
t test on the square root of the SFC counts). Incubating PBMCs from these
donors with 10 μg/mL of abacavir overnight yielded an average of 200 ± 63
SFCs per million.
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cavir, which rapidly colocalizes with HLA-B57 in the ER (27,
29). Abacavir might well be delivered to the ER directly from the
extracellular medium without traversing the cytosol, as was de-
scribed for HLA class I binding peptides (30). In this context, it
also should be noted that only a small fraction of peptide–MHC
loading events affected by abacavir can cause a physiological
effect, given that T cells have a very high sensitivity to detect
nonself peptides, which is essential to their function, and re-
markably few peptide–MHC complexes are sufﬁcient to trigger
a T-cell response (31, 32).
Together, these biochemical and structural ﬁndings provide an
explanation for why, of the more than 5,000 class I MHC alleles,
only HLA-B*5701 is affected by abacavir. They also provide
support for the altered peptide model in which the drug in effect
creates a novel HLA-B allele presenting self-peptides to which
the host has not been toleralized, analogous to the situation
occurring in HLA-mismatched organ transplantation. In organ
transplantation, preexisting class I restricted effector memory
T-cell responses to prevalent viral infections can mediate organ
rejection (33). This model of heterologous immunity might ac-
count for the clinical manifestations arising from drug-induced
altered peptide presentation and explain why only 55% of HLA-
B*5701–positive patients treated with abacavir develop hyper-
sensitivity. Other possible explanations for the incomplete posi-
tive predictive value of speciﬁc HLA alleles for abacavir and
other drug hypersensitivity syndromes and the varying clinical
features include that the relevant peptide recognized by drug-
speciﬁc T cells in the presence of drug is itself genetically poly-
morphic and/or only present in some patients or tissues, and that
only some patients have a T-cell clonotype able to respond to the
neo-antigen (34).
Over the last decade in particular, numerous HLA-associated
drug toxicities have been reported (4). Further studies should
explore in detail whether the mechanism for HLA-linked ad-
verse reactions to abacavir applies to adverse reactions against
other small molecules that seem to be immune-mediated and
HLA-linked, such as chronic beryllium disease (35) and adverse
reactions to allopurinol (36) and carbamazepine (37). Our
methods and ﬁndings are particularly signiﬁcant for such studies,
because they can be used to identify the structural, biochemical,
and functional bases of potential HLA-associated T-cell–medi-
ated drug hypersensitivities before use of a drug in humans. This
may have utility both in excluding high-risk compounds from
further development and in guiding the design of compounds
that do not bind high-risk HLA alleles or alter the repertoire
of peptides presented. The biochemical and functional assays
described here also could be used to characterize the HLA re-
striction and likely immunopathogenesis of cases of hypersensi-
tivity in early clinical studies. This could facilitate the early
introduction of HLA screening, as has been successfully imple-
mented for the prevention of abacavir hypersensitivity (38),
rather than having to rely exclusively on genetic association
studies requiring large cohorts of affected patients. Finally, these
ﬁndings have potential relevance for a broader understanding of
HLA associations in the immunopathogenesis of autoimmune
disease, infectious disease, and cancer. Such associations can be
strong yet remain enigmatic, because the molecular recognition
events underlying the associations are unclear. The discovery
that a small-molecule drug can bind within the antigen-binding
cleft of MHC and alter the repertoire of presented peptides
suggests a mechanism of action as the causative basis for HLA
associations. HLA-associated disorders may be perpetuated
by drugs, small molecules of environmental origin, or self-
metabolites that bind within the antigen-binding cleft and alter
peptide binding.
Materials and Methods
X-Ray Crystallography. Refolded β2-microglobulin, HLA-B*57:01, and aba-
cavir formed crystals at 4 mg/mL in 0.17 M sodium acetate trihydrate, 0.1 M
sodium cacodylate (pH 6.5), 25% PEG 8000, and 15% glycerol, which belong
to the space group P21 with unit cell dimensions a = 44.8 Å, b = 130.7 Å, c =
88.3 Å, α = 90°, β =1 0 4 . 6
o,a n dγ =9 0
o. Two peptide–abacavir–HLA com-
plexes in the asymmetric unit were identiﬁed by molecular replacement
using coordinates for the heavy chain and β2-microglobulin from PDB 2RFX
(HLA-B*57:01 bound to LSSPVTKSF). The peptide and ligands were not in-
cluded in the molecular replacement model. Unambiguous electron density
for the peptide and abacavir were visible in Fo-Fc difference maps and
simulated annealing omit electron density maps. The structure was reﬁned
to an R value of 18% and an Rfree value of 21% using X-ray diffraction data
to 2.0 Å.
The best crystals diffracted to a high-resolution limit of 1.9 Å. These
crystals belonged to space group P21 and contained two HLA heterodimers
(heavy chain HLA-B*57:01 and light chain β2-microglobulin) in the asym-
metric unit. The phasing was done by molecular replacement. The initially
calculated Fo-Fc difference map showed unambiguous electron density for
both the peptide and abacavir.
Abundance Calculation for Eluted Peptides. Peptide abundances were de-
termined by comparing the ion current observed for 100 fmol of an internal
standard, angiotensin I (DRVYIHPFHL), to that observed for individual pep-
tides. This femtomole quantity was then converted to peptide molecules by
multiplying by Avogadro’s number and to molecules (copies)/cell by dividing
this number by the total number of cells used to generate the sample ali-
quot injected into the mass spectrometer.
T-Cell ELISpot Assays. Before clinical samples were obtained, informed con-
sent was provided by all patients, and the study was approved by both the
Royal Perth Hospital and Murdoch University Ethics Committees. Cry-
opreserved PBMCs from abacavir-hypersensitive patients obtained at time
points previously evaluated with an abacavir-speciﬁc ELISpot assay were
thawed andcultured overnightin RPMI1640 medium containing 10%FCS, 50
U/mL of penicillin, 50 μg/mL of streptomycin, and 1 mM sodium pyruvate (F10
medium; Life Technologies). The assays were controlled using a unstimu-
lated PBMC control, a positive control for abacavir-induced endogenous li-
gand consisting of 10 μg/mL of abacavir added for the duration of the assay
culture and an abacavir 15-min pulse and wash to control for the effects of
the pulse on inducing endogenous peptide targets. Peptide ± abacavir in-
cubation times were derived to achieve the optimum balance between de-
tection of enhanced exogenous peptide binding and a restriction of
abacavir-induced endogenous peptide presentation. To set up the assay, 5 ×
10
5 PBMCs were then exposed to 10 μg/mL of exogenous peptides, either
singly or as peptide pools containing up to four peptides, in the presence or
absence of 100 μg/mL of abacavir for 15 min at 37 °C in a cell culture in-
cubator. The cells were then immediately washed with 25 volumes of ice-
cold RPMI 1640 and centrifuged for 10 min at 300 × g at 4 °C. Cells were then
resuspended in 450 μL of F10 medium containing 20U/mL of recombinant
human IL-2 (Peprotech). Then 2 × 10
5 PBMCs in duplicate were transferred
into MAIPS4510 ELISpot plates coated with 2 μg/mL of anti–IFN-γ antibody
(1-D1k; Mabtech) and blocked with F10 medium. Cells were cultured over-
night at 37 °C in a cell culture incubator. The next day, the plates were
washed with sterile PBS and incubated with anti–IFN-γ biotinylated antibody
(7-B6-1; Mabtech) for 2 h, washed, incubated for 1 h with streptavidin-HRP,
and then washed again. Plates were substrated for 8–12 min using TMB
substrate (Mabtech). After the plates were air-dried, counts were evaluated
with an AID automated microplate ELISpot reader. The following sequences
of the peptides were tested: pool 1: KTIHLTLKV, RTLAEIAKV, VTTDIQVKV,
and TVAPFNPTV; pool 2: HSIPVTVEV, KSNGTIIHV, and RTFHHGVRV; pool 3:
ATIKLQSTV, KIYEGQVEV, RSARVTVAV, and RVAGIHKKV; pool 4: RSVA-
LAVLA, KAAKIRVSV, KVAKVEPAV, and RTTETQVLV.
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